Category Archives: ALS Treatment

Macquarie University neuroscientists have developed a single-dose genetic medicine that has been proven to halt the progression of both motor neurone disease (MND) and frontotemporal dementia (FTD) in mice and may even offer the potential to reverse some of the effects of the fatal diseases. It may also hold opportunities for treating more common forms of dementia, such as Alzheimers disease, which is the second most common cause of death in Australia after heart disease. The new treatment, dubbed CTx1000, targets pathological build-ups of the protein TDP-43 in cells in the brain and spinal cord. Continue reading →

A Significant Setback in ALS Treatment Development Denali Therapeutics and Sanofi, two notable names in the pharmaceutical industry, recently suffered a significant setback in their attempt to develop a promising treatment for Amyotrophic Lateral Sclerosis (ALS). The drug, which was in a mid-stage trial, did not meet its primary objective, casting a shadow over the future prospects of this potential treatment option. ALS is a progressive neurological disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and severe physical disability. Continue reading →

HOUSTON, Feb. Continue reading →

CAMBRIDGE, Mass. - Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has announced that it will present new research on two of its investigational treatments for amyotrophic lateral sclerosis (ALS) at the upcoming Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in Orlando, Florida. Continue reading →

A Breakthrough in ALS Treatment Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by rapid, progressive loss of motor neurons in the brain and spinal cord. This debilitating condition, for which there is currently no cure, may soon see a ray of hope with the discovery of a new pharmacological inhibitor, FP802. Recent research funded by the German Research Foundation, the European Research Council, and the Alexander von Humboldt Foundation has unveiled the potential of this inhibitor in the treatment of ALS. Continue reading →

Groundbreaking Discovery by Heidelberg University In a major advancement towards the treatment of amyotrophic lateral sclerosis (ALS), a research team led by Prof. Dr. Continue reading →

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease, is a progressive neurodegenerative condition marked by the loss of motor neurons, cells that control voluntary muscles. This fatal disease has been a longstanding challenge for researchers and physicians, with no effective cure available Continue reading →

A major breakthrough in the treatment of amyotrophic lateral sclerosis, known as ALS, can potentially help stop the disease in its tracks in as much as half of the cases in the U.S., a Northeastern University scientist says. Jeffrey Agar, associate professor of chemistry and pharmaceutical sciences at Northeastern, has spent the last 12 years studying the mechanism of ALS and researching ways to prevent its progression. Continue reading →

Aaron Lazar is opening up about his diagnosis with amyotrophic lateral sclerosis (ALS), and revealing why he's not focused on trying to fight the disease for which there is no cure, but instead move through life with courage and hope. The stage veteran known for two decades of roles on Broadway and on tour in musicals like The Light in the Piazza, Dear Evan Hansen, Les Misrables, A Little Night Music and The Last Ship went public in January with the news that he had the progressive neurogenerative disorder, after being diagnosed two years ago. During a candid interview on The Broadway Show with Tamsen Fadal, the 47-year-old actor and singer explained he's since been on a healing journey" focused on taking care of his mind, body and spirit. Continue reading →

image: The image above describes the changes in the mean scores for the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) for ALS patients treated with CL2020. Continue reading →